Non-metastatic high-risk prostate cancer patients with biochemical relapse only after local treatment. A prospective randomized phase III study comparing hormonal therapy +/--docetaxel.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Docetaxel (Primary) ; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2017 Results (n=250) presented at the 42nd European Society for Medical Oncology Congress
- 04 Jun 2013 Quality-of-life results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.